Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)
27 juil. 2023 09h00 HE
|
Disc Medicine Inc
WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
22 juin 2023 16h15 HE
|
Disc Medicine Inc
WATERTOWN, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...
Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
13 juin 2023 22h39 HE
|
Disc Medicine Inc
WATERTOWN, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
12 juin 2023 16h00 HE
|
Disc Medicine Inc
WATERTOWN, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...
Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress
09 juin 2023 07h00 HE
|
Disc Medicine Inc
Consistent and dose-dependent reductions of protoporphyrin IX (PPIX), the disease-causing metabolite in EPP, were observed in patients treated with bitopertin Patients reported significant...
Disc Medicine to Participate in the Jefferies Healthcare Conference
31 mai 2023 16h00 HE
|
Disc Medicine Inc
WATERTOWN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update
15 mai 2023 07h00 HE
|
Disc Medicine Inc
Two ongoing Phase 2 studies of bitopertin in EPP; initial safety and efficacy data from open-label BEACON trial to be presented at the European Hematology Association (EHA) Congress in June 2023;...
Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress
11 mai 2023 10h15 HE
|
Disc Medicine Inc
WATERTOWN, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference
21 avr. 2023 08h30 HE
|
Disc Medicine Inc
WATERTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)
13 avr. 2023 11h00 HE
|
Disc Medicine Inc
WATERTOWN, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...